Detalhe da pesquisa
1.
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma.
Future Oncol
; 19(6): 463-471, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37083162
2.
Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.
Future Oncol
; 18(16): 2029-2039, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196866
3.
Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
Future Oncol
; 17(22): 2883-2892, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33858190
4.
Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
Ann Hematol
; 99(6): 1241-1249, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32307568
5.
A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia.
Future Oncol
; 15(16): 1895-1909, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30912462
6.
A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia.
Future Oncol
; 15(6): 663-681, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30450960
7.
A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.
BMC Dermatol
; 19(1): 8, 2019 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31174539
8.
Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
Cancer
; 124(3): 587-595, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29072772
9.
Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom.
Health Qual Life Outcomes
; 16(1): 66, 2018 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29669568
10.
Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
Acta Derm Venereol
; 98(3): 340-345, 2018 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29182790
11.
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
J Am Acad Dermatol
; 75(6): 1162-1170.e3, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27692733
12.
Economic Burden of Psoriasis and Potential Cost Offsets with Biologic Treatment: A Swedish Register Analysis.
Acta Derm Venereol
; 96(5): 651-7, 2016 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26716136
13.
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
BMC Dermatol
; 16(1): 15, 2016 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27716172
14.
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
BMC Gastroenterol
; 15: 14, 2015 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25651782
15.
Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States.
J Am Acad Dermatol
; 73(4): 585-593.e3, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26253364
16.
Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study.
Acta Derm Venereol
; 95(7): 809-15, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25766866
17.
Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.
JMIR Cancer
; 8(3): e39068, 2022 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36136395
18.
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.
PLoS One
; 17(5): e0267979, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550641
19.
Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK.
Pharmacoecon Open
; 5(4): 677-691, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34181204
20.
An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
Curr Med Res Opin
; 37(5): 801-809, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33733983